AU4775797A - Process for the determination of app secretase modulators and the use thereof as agents in the treatment of alzheimer's disease - Google Patents

Process for the determination of app secretase modulators and the use thereof as agents in the treatment of alzheimer's disease

Info

Publication number
AU4775797A
AU4775797A AU47757/97A AU4775797A AU4775797A AU 4775797 A AU4775797 A AU 4775797A AU 47757/97 A AU47757/97 A AU 47757/97A AU 4775797 A AU4775797 A AU 4775797A AU 4775797 A AU4775797 A AU 4775797A
Authority
AU
Australia
Prior art keywords
alzheimer
disease
agents
determination
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47757/97A
Inventor
Thomas Dyrks
Marion Hartel
Jonathan-David Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU4775797A publication Critical patent/AU4775797A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU47757/97A 1996-09-24 1997-09-22 Process for the determination of app secretase modulators and the use thereof as agents in the treatment of alzheimer's disease Abandoned AU4775797A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19641180A DE19641180A1 (en) 1996-09-24 1996-09-24 A method of displaying APP secretase modulation and its use as an agent for the treatment of Alzheimer's disease
DE19641180 1996-09-24
PCT/EP1997/005149 WO1998013488A2 (en) 1996-09-24 1997-09-22 Process for the determination of app secretase modulators and the use thereof as agents in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
AU4775797A true AU4775797A (en) 1998-04-17

Family

ID=7807996

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47757/97A Abandoned AU4775797A (en) 1996-09-24 1997-09-22 Process for the determination of app secretase modulators and the use thereof as agents in the treatment of alzheimer's disease

Country Status (4)

Country Link
AU (1) AU4775797A (en)
DE (1) DE19641180A1 (en)
WO (1) WO1998013488A2 (en)
ZA (1) ZA978557B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US6844148B1 (en) 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
KR20070004143A (en) 1998-09-24 2007-01-05 파마시아 앤드 업존 캄파니 엘엘씨 Alzheimer's disease secretase
US6699671B1 (en) 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US6245884B1 (en) 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US6313268B1 (en) 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
US7456007B1 (en) 1998-12-31 2008-11-25 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US7115410B1 (en) 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
JP4653318B2 (en) 1999-02-10 2011-03-16 エラン ファーマシューティカルズ，インコーポレイテッド β-secretase enzyme composition and method
DE19920514A1 (en) * 1999-05-05 2000-11-16 Boehringer Ingelheim Pharma Methods for finding proteases that specifically cleave membrane-bound substrates
AU5773500A (en) 1999-06-28 2001-01-31 Board Of Trustees Of The University Of Illinois, The Inhibitors of memapsin 2 and use thereof
DE19941039A1 (en) * 1999-08-28 2001-03-01 Boehringer Ingelheim Pharma gamma-secretase in vitro test system
US7514408B1 (en) 1999-12-02 2009-04-07 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
WO2001058476A2 (en) * 2000-02-11 2001-08-16 The European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
AU2000238331A1 (en) * 2000-04-05 2001-10-15 Esbatech Ag Method for identify polypeptides with protease activity
CA2313828A1 (en) * 2000-08-01 2002-02-01 Institut De Recherches Cliniques De Montreal/Ircm Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
WO2002062824A2 (en) * 2001-02-05 2002-08-15 Andrx Corporation Method of treating amyloid ? precursor disorder
CA2464736A1 (en) 2001-10-23 2003-05-15 Oklahoma Medical Research Foundation Beta-secretase inhibitors and methods of use
US7045311B2 (en) 2001-10-25 2006-05-16 Monogram Biosciences, Inc. Whole cell assay systems for cell surface proteases
CH698246B1 (en) * 2001-12-20 2009-06-30 Hoffmann La Roche Test to identify inhibitors of beta secretases.
WO2003087842A1 (en) * 2002-04-18 2003-10-23 Esbatech Ag Method for the identification of modulators of a secretase activity
JP2004000060A (en) * 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd METHOD FOR SCREENING COMPOUND AFFECTING PRODUCTION OF AMYLOID beta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327960A1 (en) * 1988-02-11 1989-08-16 F. Hoffmann-La Roche Ag Secretable forms of alkaline phosphatase
US5851787A (en) * 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
AU679675B2 (en) * 1992-05-11 1997-07-10 Bayer Corporation Methods for detecting beta amyloid precursor protein processing enzymes
EP0915090A1 (en) * 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
WO1994010569A1 (en) * 1992-10-26 1994-05-11 Schenk Dale B METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
JPH11507538A (en) * 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β-secretase, antibodies to β-secretase, and assays for detecting β-secretase inhibition

Also Published As

Publication number Publication date
ZA978557B (en) 1998-03-26
WO1998013488A3 (en) 1998-09-11
WO1998013488A2 (en) 1998-04-02
DE19641180A1 (en) 1998-03-26

Similar Documents

Publication Publication Date Title
AU4775797A (en) Process for the determination of app secretase modulators and the use thereof as agents in the treatment of alzheimer's disease
AU4054297A (en) Manipulations of nitrosative and oxidatives stress in the treatment of disease
EP1007048A4 (en) Identification of agents for use in the treatment of alzheimer's disease
AU5716898A (en) Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
HUP9800033A3 (en) Compositions for the treatment of dermatological disorders and methods for their use
AU3689595A (en) Device for use in the laser treatment of biological tissue (variants thereof)
AU7623096A (en) Use of epinastine in the treatment of pain
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
AU3590897A (en) Traveler's quarters
IL122733A0 (en) Pharmaceutical compositions for use in the treatment of allergic asthma
AU3683800A (en) Device for the therapeutic and cosmetic photo-processing of biological tissues and method for using the same
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
AU3279395A (en) Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
IL105216A0 (en) Method and kit for the diagnosis of alzheimer's disease
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
EP0892632A4 (en) Compositions useful in the phototherapeutic treatment of proliferative skin disorders
EP1011644A4 (en) Methods and apparatus for treatment of parkinson's disease
IL127146A0 (en) Transdermal propentofylline compositions for the treatment of alzheimer's disease
AU5053296A (en) Pharmaceutical agents for the treatment of Alzheimer's disease
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
AU5963396A (en) Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders
AUPN115095A0 (en) Analysis of and compositions and methods for the treatment of disease
IL117191A0 (en) Process for the preparation of oxazolidinones and their use
AU7622798A (en) Application of thalidomide to the treatment of Parkinson's disease and Parkisonian syndromes
AU2137595A (en) Use of arylpiperazine derivatives for the treatment of Parkinson's disease and psychosis